Regenacy Pharmaceuticals, LLC

University of Texas System

Biogen Idec Ma Inc.

Matthew B Jarpe

Cobi J Heijnen

Annemieke Kavelaars

Olga Golonzhka

Karen Krukowski

Steven Donald Miklasz

Brian A Elenbaas

Stephen E Fawell

Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.

Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.

HDAC inhibitors for the treatment of diabetic peripheral neuropathy

This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.

Antibodies to the human prolactin receptor

Growing community of inventors

Quincy, MA, United States of America

Matthew B Jarpe